JP2013522291A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522291A5
JP2013522291A5 JP2013500053A JP2013500053A JP2013522291A5 JP 2013522291 A5 JP2013522291 A5 JP 2013522291A5 JP 2013500053 A JP2013500053 A JP 2013500053A JP 2013500053 A JP2013500053 A JP 2013500053A JP 2013522291 A5 JP2013522291 A5 JP 2013522291A5
Authority
JP
Japan
Prior art keywords
group
amino acid
acid selected
peptide
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013500053A
Other languages
English (en)
Japanese (ja)
Other versions
JP5730983B2 (ja
JP2013522291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/024604 external-priority patent/WO2011115712A2/en
Publication of JP2013522291A publication Critical patent/JP2013522291A/ja
Publication of JP2013522291A5 publication Critical patent/JP2013522291A5/ja
Application granted granted Critical
Publication of JP5730983B2 publication Critical patent/JP5730983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013500053A 2010-03-19 2011-02-11 Ｔｆｐｉ阻害剤および使用方法 Active JP5730983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31575810P 2010-03-19 2010-03-19
US61/315,758 2010-03-19
PCT/US2011/024604 WO2011115712A2 (en) 2010-03-19 2011-02-11 Tfpi inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015002795A Division JP6195858B2 (ja) 2010-03-19 2015-01-09 Ｔｆｐｉ阻害剤および使用方法

Publications (3)

Publication Number Publication Date
JP2013522291A JP2013522291A (ja) 2013-06-13
JP2013522291A5 true JP2013522291A5 (cg-RX-API-DMAC7.html) 2013-07-25
JP5730983B2 JP5730983B2 (ja) 2015-06-10

Family

ID=44649759

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013500053A Active JP5730983B2 (ja) 2010-03-19 2011-02-11 Ｔｆｐｉ阻害剤および使用方法
JP2015002795A Active JP6195858B2 (ja) 2010-03-19 2015-01-09 Ｔｆｐｉ阻害剤および使用方法
JP2017055402A Pending JP2017105851A (ja) 2010-03-19 2017-03-22 Ｔｆｐｉ阻害剤および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015002795A Active JP6195858B2 (ja) 2010-03-19 2015-01-09 Ｔｆｐｉ阻害剤および使用方法
JP2017055402A Pending JP2017105851A (ja) 2010-03-19 2017-03-22 Ｔｆｐｉ阻害剤および使用方法

Country Status (12)

Country Link
US (5) US8450275B2 (cg-RX-API-DMAC7.html)
EP (2) EP3146977B1 (cg-RX-API-DMAC7.html)
JP (3) JP5730983B2 (cg-RX-API-DMAC7.html)
KR (2) KR101784030B1 (cg-RX-API-DMAC7.html)
CN (2) CN105566490A (cg-RX-API-DMAC7.html)
AU (1) AU2011227714B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012023559A2 (cg-RX-API-DMAC7.html)
CA (1) CA2793465C (cg-RX-API-DMAC7.html)
DK (1) DK2547355T3 (cg-RX-API-DMAC7.html)
ES (2) ES2983470T3 (cg-RX-API-DMAC7.html)
NZ (3) NZ710434A (cg-RX-API-DMAC7.html)
WO (1) WO2011115712A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
PH12012501742A1 (en) 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
EP3563872A1 (en) * 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US20160009817A1 (en) * 2013-03-15 2016-01-14 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
CN105473619B (zh) 2013-07-19 2020-12-15 诺和诺德股份有限公司 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
JP6711761B2 (ja) 2014-02-28 2020-06-17 バクスアルタ インコーポレイテッド ペプチド及びその使用方法
US10300154B2 (en) 2014-09-17 2019-05-28 David R Elmaleh Anticoagulant derivatives for cardiovascular imaging
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
EP3518953A4 (en) 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
MY209484A (en) 2018-03-02 2025-07-11 Elicio Therapeutics Inc Cpg amphiphiles and uses thereof
KR102337683B1 (ko) 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
US20210318338A1 (en) * 2018-10-04 2021-10-14 Thrombosis And Coagulation Ab Method for the determination of protein s levels
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (ja) 1983-06-25 1985-01-14 古河電気工業株式会社 回路基板用半田付炉
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6153985A (ja) 1984-08-25 1986-03-18 松下電工株式会社 ブラインド
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
AU4784693A (en) 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
DE69726281T2 (de) 1996-03-25 2004-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
JP2002503701A (ja) 1998-02-18 2002-02-05 ハーバー−ユーシーエルエイ リサーチ アンド エデュケーション インスティテュート 抗菌性ペプチドおよび誘導したメタペプチド
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
CN1368886A (zh) 1999-07-23 2002-09-11 斯克里普斯研究所 用于测定全血中的凝固因子活性的方法
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
AU1615701A (en) 1999-11-16 2001-05-30 General Hospital Corporation, The Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1593389A1 (en) 2000-05-10 2005-11-09 Novo Nordisk Health Care AG Pharmaceutical composition comprising a factor VIIa and a factor XIII
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
WO2002033089A2 (en) * 2000-10-05 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
MXPA04000415A (es) 2001-07-20 2004-11-22 Novo Nordisk Healthcare Ag Composicion farmaceutica que comprende polipeptidos del factor vii y polipeptidos del factor xi.
WO2003015750A1 (en) 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003028840A2 (en) 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003039579A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
CA2512590A1 (en) 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
WO2004092410A2 (en) 2003-04-15 2004-10-28 Thiesen Hans-Juergen Method for diagnosing rheumatoid arthritis or osteoarthritis
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
CA2532874A1 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005024006A2 (en) 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP1668371B1 (en) 2003-09-24 2012-05-09 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
CN101094698A (zh) 2003-09-29 2007-12-26 汉莫堤克科技公司 医学表面的生物相容,生物稳定的涂层
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
AU2004290869A1 (en) 2003-11-20 2005-06-02 Novo Nordisk Health Care Ag Therapeutic use of factor XI
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
CA2546343A1 (en) * 2003-11-20 2005-06-09 Sanofi Pasteur, Inc. Methods for purifying pertussis toxin and peptides useful therefor
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
JP2007523705A (ja) 2004-02-28 2007-08-23 ヘモテック アーゲー 医療用品表面の生体適合性コーティング、方法、および使用
US20090053193A1 (en) 2004-05-11 2009-02-26 Novo Nordisk Healthcare A/G Use of Factor VIIa for the Treatment of Burn Trauma
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
EP2165711B1 (en) 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2005123916A2 (en) 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Glycosylation-disrupted factor vii variants
US20090004175A1 (en) 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
WO2006089966A2 (en) 2005-02-28 2006-08-31 Novo Nordisk Health Care Ag Fxiii variants with improved properties
EP1869082B1 (en) 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
WO2006116546A1 (en) 2005-04-27 2006-11-02 Baxter International Inc. Surface-modified microparticles and methods of forming and using the same
KR20080008364A (ko) 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
ES2809173T3 (es) 2006-02-09 2021-03-03 Braun Melsungen Ag Método de revestimiento de balón plegable
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US9096839B2 (en) 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR101486931B1 (ko) 2007-02-23 2015-01-27 박스터 인터내쇼날 인코포레이티드 해조류 추출물로부터 푸코이단을 정제하는 방법
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
US20110027337A1 (en) 2007-12-21 2011-02-03 Ifxa A/S Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
EP2323694A1 (en) 2008-08-06 2011-05-25 Novo Nordisk Health Care AG Conjugated proteins with prolonged in vivo efficacy
DK2379096T3 (da) * 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
AU2012236296A1 (en) 2011-04-01 2013-10-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Similar Documents

Publication Publication Date Title
JP2013522291A5 (cg-RX-API-DMAC7.html)
KR101948463B1 (ko) Tfpi 저해제 및 사용 방법
AU2017221855B2 (en) Tfpi inhibitors and methods of use
JP2012512915A5 (cg-RX-API-DMAC7.html)
US20140065069A1 (en) Materials and Methods Relating to Cardiovascular Imaging
US20140296479A1 (en) D-aptide and retro-inverso aptide with maintained target affinity and improved stability
CA2939658C (en) Peptides and methods of use
US20230021979A1 (en) Methods for developing virus protein-specific capture agents, capture agents, and methods of using the capture agents
WO2007129077A2 (en) Imaging agent
AU2014262256A1 (en) Tfpi inhibitors and methods of use
HK1206282B (en) Tfpi inhibitors and methods of use